advanced

advanced

Satipharm launches new Advanced CBD products – safeguarding your health and wellness


Health and wellness company Satipharm has launched their new CBD Advanced range starting with two products – Active and Focus. In addition to CBD, these capsules include targeted vitamins to help safeguard your health.

The Active capsules contain Satipharm’s patented CBD microbeads plus vitamins A, D, K and E. These vitamins have been specifically chosen to complement the CBD, for the effects they have on muscles, skin, bones and vision. Importantly, the Active capsules contain 200% of the Recommended Daily Allowance of vitamin D, which supports the functioning of the immune system. This ensures the body has adequate levels of vitamin D needed to produce the antimicrobial proteins that kill viruses and bacteria.

The Focus capsules contain the CBD microbeads, plus a targeted selection of B vitamins to support mental performance, psychological function and the reduction of tiredness & fatigue. B vitamins are necessary for creating neurotransmitters that regulate emotions, including serotonin and dopamine. Vitamin B6 also contributes to normal immune function.

Jonathan Hartshorn, CEO of Satipharm commented: “Supporting the health of our minds and bodies is always important. Getting quality sleep, minimising stress and getting sufficient vitamin D are three simple ways to help our immune systems function well and fight infections. The launch of our Advanced Active and Focus products enables individuals to take the right supplements to support their mental and physical wellbeing.”

Satipharm’s CBD Advanced range is powered by their patented Gelpell® technology which protects the cannabinoids by embedding them in microspheres. This Gelpell® technology has been clinically proven to increase the bioavailability of CBD, making Satipharm capsules the best way to take CBD. Taking a Satipharm 10mg CBD capsule is equivalent to taking 3.5 times the dose (35mg) of CBD oil.

About Satipharm
Satipharm is a health and wellness company, specialising in the development of cannabinoid-based products and focusing on clinical evidence-based recommendations to customers and patients. The Company’s mission is to deliver the highest quality products designed specifically for the needs of its consumers.

CBD (reference Dr Perry Solomon, CMO HelloMD)
CBD, or cannabidiol, is a naturally occurring active cannabinoid found in the cannabis plant. Unlike THC, or tetrahydrocannabinol, CBD has no intoxicating effect (high). These cannabinoids are just two of at least 113 identified in cannabis. CBD is most commonly used to treat insomnia, depression, anxiety and joint pain. Preliminary clinical reports indicate CBD to have analgesic properties, in addition to anti-inflammatory, anti-anxiety, anti-psychoactive, and anti-convulsant properties. CBD achieves this by directly (or indirectly) affecting neurological receptors responsible for pain modulation, inflammation regulation, and mood and stress management.

Bioavailability – is the proportion of a consumed substance which enters the bloodstream when introduced to the body and so is able to have an active effect on the body. A substance (such as CBD oil) may be readily absorbed but undergo significant metabolism by the liver before the active cannabinoids reach the circulation, thereby reducing its effect in the body.

Source link

Sven Simon, Member of the European Parliament, Visits Exide’s Advanced Manufacturing Facility in Büd


Battery manufacturer Exide Technologies, a global provider of stored electrical energy solutions, today hosted a visit by Sven Simon, Member of the European Parliament, at its manufacturing plant in Büdingen, Germany. The visit included discussions about Exide’s industrial and environmental activities, and the future of battery technology in reducing carbon emissions.

Simon, a member of the Christian Democratic Union party of Germany (CDU), was elected to the European Parliament for the first time in 2019. The MEP, a law professor with an interest in sustainable growth, was briefed on the innovation and next-generation manufacturing being conducted at the Exide plant, and also received an official tour.

Exide, as a member of EUROBAT (the Association of European Automotive and Industrial Battery Manufacturers), is engaged in efforts to decarbonize the battery industry. As it aims for sustainability in energy production and storage, its strong investment in R&D has put it at the cutting edge of battery solutions in the steady transition to a decarbonized energy sector.

“We were delighted to welcome Sven Simon MEP to our facilities in Büdingen,” said Karsten Kurz, Director of Environmental Affairs, Europe, at Exide Technologies. “We spoke about high-quality manufacturing jobs, growth opportunities in the battery market, and the ability for battery technology to bring stability to energy markets and reduce dependence on fossil fuels.”

Source link

GPI forecasts healthcare product price potential using advanced analytics


Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices for new products by blending its market-leading database of market access information, GPI pulse¬TM, with a framework that maps payer value perception and behavior.

The framework allows pricing teams to use data to anticipate payer response for early clinical stage drugs – typically an involved and uncertain process. GPI has validated the method in the UK and France and is expanding it across countries captured by GPI pulse. GPI’s framework uses multi-criteria decision analysis and published value frameworks. It is built on GPI’s deep domain knowledge, access to data and rigorous approach to developing and testing new analytics.

“The concept of value in healthcare is key to pricing,” said GPI’s founder and CEO, Preeti Patel, “yet there is little global standardization. We’ve quantified global HTA assessment factors and value drivers into a framework that allows teams to understand the variation in value perception across markets and impact on price.”

GPI has a growing footprint in pricing and market access analytics. GPI pulse TM is a revolutionary platform that captures real-time global price data and reimbursement decisions across 90+ markets at a product and indication level. It supports a wide range of innovative analytical tools, insight generation and P&MA data architecture.

GPI’s customers include price, access and commercial teams within biopharma, who utilize GPI’s data and analytical capabilities to better understand pricing scenarios at an early stage and support market access planning and strategy across the product lifecycle.

About GPI
Global Pricing Innovations (GPI) is a market leader in business intelligence, analytics and innovative solutions for the life science industry. GPI delivers integrated insights, technology solutions and strategy development that make a measurable difference to price, access & commercial teams within biopharma. Our combination of innovative technology platforms, data, and analytical expertise enable industry to drive sustainable price and access strategies and agile infrastructure. GPI’s cultural values are centered on promoting the ambitions of inspiring and talented individuals so together we can make a difference to the life sciences industry. We value collaboration, innovation, openness and authenticity, and work as ‘one team’ with our clients.

As a global company, GPI has operating units and service partners throughout the world. GPI  is a privately held company headquartered in London, UK.

Source link